Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.

He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'

Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.

While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

Show full CV Hide full CV

Latest news & insights

White microscope on yellow background
Life sciences & healthcare

Aspen Healthcare sold to Canadian-based property trust

27 September 2021

by Andrew McLean and Andrew Edge

Click here to find out more
Pipette adding sample to petri dish
Life sciences & healthcare

Advising Apollo Therapeutics on $145 million financing

21 June 2021

by Andrew Edge and Chris Cowley

Click here to find out more
gavel close-up
Patents & innovation

The Disproportionality Defense – Will it change the legal landscape

29 September 2022

by multiple authors

Click here to find out more
Close up of a walnut on grey background

The challenging timeline of patent infringement proceedings before the Unified Patent Court

23 September 2022

by multiple authors

Click here to find out more

Related people

Meet me at

There are no upcoming events